NASDAQ:ADAG - Adagene Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 420.83 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.88
▼ -0.09 (-3.03%)

This chart shows the closing price for ADAG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adagene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADAG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADAG

Analyst Price Target is $15.00
▲ +420.83% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Adagene in the last 3 months. The average price target is $15.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 420.83% upside from the last price of $2.88.

This chart shows the closing price for ADAG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Adagene.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/18/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2022Morgan StanleyLower Price TargetOverweight$27.00 ➝ $15.00Low
1/6/2022Morgan StanleyLower Price TargetOverweight$33.00 ➝ $27.00High
7/16/2021Morgan StanleyLower Price TargetOverweight$34.00 ➝ $33.00High
3/8/2021Jefferies Financial GroupInitiated CoverageBuy$33.00High
3/8/2021Morgan StanleyInitiated CoverageOverweight$34.00High
3/5/2021The Goldman Sachs GroupInitiated CoverageBuy$29.00High
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
11/20/2021
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/19/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/18/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/20/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/19/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Adagene logo
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Read More

Today's Range

Now: $2.88
Low: $2.76
High: $2.99

50 Day Range

MA: $3.79
Low: $2.88
High: $4.85

52 Week Range

Now: $2.88
Low: $2.76
High: $20.98

Volume

23,692 shs

Average Volume

30,586 shs

Market Capitalization

$126.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Adagene?

The following Wall Street analysts have issued reports on Adagene in the last year: Morgan Stanley, and Zacks Investment Research.
View the latest analyst ratings for ADAG.

What is the current price target for Adagene?

0 Wall Street analysts have set twelve-month price targets for Adagene in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 420.8%.
View the latest price targets for ADAG.

What is the current consensus analyst rating for Adagene?

Adagene currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADAG will outperform the market and that investors should add to their positions of Adagene.
View the latest ratings for ADAG.

How do I contact Adagene's investor relations team?

Adagene's physical mailing address is 4F BUILDING C14 NO. 218 XINGHU STREET SUZHOU INDUSTRIAL PARK, JIANGSU F4, 215123. The company's listed phone number is 86-512-8777-3632 and its investor relations email address is [email protected] The official website for Adagene is www.adagene.com. Learn More about contacing Adagene investor relations.